{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"14.000","floor":"12.000"},"ipodate":{"start":"2020-12-09 00:00:00","end":"2020-12-14 00:00:00"},"minimumcapital":"4242.32","subscribed":"299.59","marketcap":"106.35億","H_marketcap":"--","pe":"--","codesrate":"15.00","link":"https://staticpdf.iqdii.com/stockdata/notice/01167/2020/2020120900014_c.pdf","ipopricing":"14.000","resultdate":"2020-12-18 00:00:00","enddate":"2020-12-14 00:00:00","listeddate":"2020-12-21 00:00:00","issuenumber":"9647.61萬","issuenumberhK":"4824.00萬","issuenumberother":"4823.61萬","grayprice":"16.70","sponsors":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司","raisemoney":"126310.00萬","use":"1、約88.0%，或143.4百萬美元（1,111.5百萬港元），將主要用于產品的臨床開發及商業化；\n2、約8.0%，或13.0百萬美元（101.0百萬港元）將用于建造符合GMP標準的內部生產設施；\n3、約4.0%，或6.5百萬美元（50.5百萬港元）將用于我們的一般企業及營運資金用途。","shares":300,"leadagent":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司","bookrunners":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司","coordinator":"高盛(亞洲)有限責任公司,中國國際金融香港證券有限公司","firstDayOpen":"15.98","IsEiio":0,"Interestdays":4,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E01167","name":"加科思－Ｂ","fullname":"加科思藥業集團有限公司"},"institutioninfo":{"principaloffice":"中國北京市北京經濟技術開發區科創六街88號F2樓","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"王印祥","secretary":"薛青,楊靜文","telephone":"(8610) 5631 5466 ","substantialshareholders":"王印祥及一致行動人士(36.48%),晟德大藥廠股份有限公司(15.64%),啟明創投(10.77%),LAV(7.93%),HH SPR-III Holdings Limited(7.49%)","principalactivities":"公司是一家臨床階段制藥公司，專注于創新腫瘤療法的自主發現和開發。","website":"http://www.jacobiopharma.com"},"managerinfo":[{"managername":"王印祥","post":"董事長、首席執行官兼執行董事","rankno":1},{"managername":"王曉潔","post":"行政總裁兼執行董事","rankno":2},{"managername":"胡邵京","post":"研發總裁兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"LAV Prime Limited","shareholding":"8,305,200.0","percentage":8.61,"ReleaseDate":"2021-06-21 00:00:00","relatedparty":"LAV Biosciences Fund V, L.P.","subsidiary":["LAV Prime Limited","LAV Amber Limited"],"InverstorType":"公司"},{"institutionname":"Matthews Asia Funds","shareholding":"8,305,200.0","percentage":8.61,"ReleaseDate":"2021-06-21 00:00:00","relatedparty":"Matthews International Capital Management, LLC","subsidiary":["Matthews Asia Funds","銘基基金"],"InverstorType":"基金"},{"institutionname":"Octagon Investments Master Fund LP","shareholding":"5,536,800.0","percentage":5.74,"ReleaseDate":"2021-06-21 00:00:00","relatedparty":"Octagon Capital Advisors LP","subsidiary":["Octagon Investments Master Fund LP"],"InverstorType":"基金"},{"institutionname":"HBC Asia Healthcare Opportunities V LLC","shareholding":"5,536,800.0","percentage":5.74,"ReleaseDate":"2021-06-21 00:00:00","relatedparty":"Hudson Bay Capital Management LP","subsidiary":["HBC Asia Healthcare Opportunities V LLC","Hudson Bay Master Fund LTD","HBC Asia Healthcare Opportunities VII LLC"],"InverstorType":"基金"}],"TotalShareholdingPercentage":34.44},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":9}